INVO Fertility Launches PRP Therapy at Wisconsin Clinic - Product and Market Analysis

This analysis is based on the INVO Fertility official press release [10] published on June 30, 2025, which announced the addition of Platelet-Rich Plasma (PRP) therapy to the company’s Wisconsin Fertility Institute center.

INVO Fertility’s PRP therapy launch represents a strategic expansion of its fertility treatment portfolio, leveraging the company’s existing clinical infrastructure at the Wisconsin Fertility Institute [10]. The therapy utilizes autologous blood processing to concentrate platelets containing growth factors that stimulate tissue repair and regeneration, specifically targeting intraovarian injection for follicular activation and endometrial health enhancement [3][4]. This minimally invasive approach positions INVO Fertility to capture patients seeking alternatives before considering more expensive options like egg donation or surrogacy [10].

The product launch aligns with INVO Fertility’s integrated care model, combining the new PRP therapy with existing INVOcell technology and traditional IVF services [10]. The Wisconsin Fertility Institute’s recognition on Newsweek’s Best Fertility Clinics list [9] provides additional credibility for the new offering, potentially enhancing patient adoption rates.

The PRP therapy introduction comes during a challenging financial period for INVO Fertility. The company reported Q2 2025 revenue of $1.86 million (1% year-over-year growth) with a widening net loss of $3.2 million compared to $2.2 million in Q2 2024 [8]. The company has experienced seven consecutive years of losses and underwent a 1-for-3 reverse stock split effective July 21, 2025 [8], indicating ongoing financial pressures.

However, the timing capitalizes on substantial market growth opportunities. The global fertility market is projected to grow from $39.27 billion in 2025 to $85.53 billion by 2034, representing a 9.03% CAGR [6]. Alternative estimates from Mordor Intelligence project growth from $34.63 billion in 2025 to $49.02 billion by 2030 (7.21% CAGR) [7], indicating strong market tailwinds regardless of specific projections.

INVO Fertility operates three clinics in the United States (two INVO Centers and one IVF clinic) [2], providing a focused but growing geographic presence. The company’s strategy emphasizes building, acquiring, and operating fertility clinics while distributing its INVOcell technology to third-party clinics [10]. The PRP therapy addition supports this dual revenue stream approach of both clinic services and technology distribution.

The competitive landscape for fertility PRP therapy is emerging, with established fertility clinics increasingly offering PRP as adjunct therapy, specialized PRP providers focusing on regenerative medicine applications, and research institutions conducting clinical trials [10]. INVO Fertility’s competitive advantages include its integrated care model, proprietary technology portfolio, and established clinical infrastructure [10].

The PRP therapy targets several high-value patient segments, including women with diminished ovarian reserve (DOR), patients with thin uterine lining, and individuals seeking alternatives before egg donation or surrogacy [10]. This strategic positioning addresses significant unmet needs in the fertility market, particularly for patients who have had limited success with conventional fertility treatments.

The therapy’s cost-effectiveness relative to advanced reproductive technologies like egg donation and surrogacy [10] could provide a competitive advantage in price-sensitive market segments. By leveraging existing clinic infrastructure and the patient’s own biological material, INVO Fertility can potentially maintain lower costs while delivering innovative treatment options.

A critical insight is the experimental nature of PRP therapy in fertility treatment. Dr. Gretchen Collins from Wisconsin Fertility Institute acknowledged that “while its use in fertility is still being studied, PRP has shown value in other areas of medicine” [10]. This regulatory ambiguity creates both opportunities and risks, as the therapy operates in a space with evolving clinical evidence and reimbursement policies.

The growing research supporting PRP’s potential benefits [3][4] provides a foundation for market adoption, but varying results across studies suggest the need for continued clinical validation and standardized protocols. Market reception will likely depend on the accumulation of positive clinical outcomes and insurance coverage development.

The PRP therapy launch coincides with INVO Fertility’s operational streamlining efforts, including the divestiture of NAYA Therapeutics while retaining a minority stake to concentrate on core fertility operations [9]. This focused approach could enhance resource allocation for the new therapy’s implementation and marketing.

The industry value chain impact includes potential increased demand for blood processing equipment and PRP preparation kits upstream, integration with existing fertility clinic workflows midstream, and expanded treatment options downstream that could reduce progression to more expensive alternatives [10].

: PRP therapy in fertility treatment remains experimental with varying clinical study results [3][4], potentially limiting adoption rates and reimbursement opportunities.

: The company’s ongoing financial challenges, including seven consecutive years of losses and widening Q2 2025 net losses [8], may constrain marketing investments and expansion capabilities for the new therapy.

: The relatively low barrier to implementing PRP therapy in existing fertility clinics could lead to rapid market saturation and intensified competition from established players with greater resources.

: The evolving regulatory landscape for PRP applications in reproductive medicine could affect treatment availability and reimbursement policies [10].

: The projected fertility market expansion to $85.53 billion by 2034 [6] provides substantial growth opportunities for innovative treatment providers.

: Early adoption of PRP therapy in established fertility clinics could capture market share before widespread competitor implementation.

: The therapy’s potential affordability compared to egg donation and surrogacy [10] could attract price-sensitive patient segments and expand market reach.

: Combining PRP therapy with existing INVOcell technology and traditional IVF services [10] creates comprehensive treatment packages that could enhance patient retention and average revenue per patient.

INVO Fertility’s PRP therapy launch at the Wisconsin Fertility Institute represents a strategic product expansion targeting the growing fertility market projected to reach $85.53 billion by 2034 [6]. The minimally invasive therapy uses autologous blood components to address thin uterine lining and diminished ovarian reserve [10], positioning it as an innovative alternative to more expensive reproductive technologies.

The company operates three U.S. clinics and maintains a dual revenue stream model of clinic services and technology distribution [2][10]. Despite the product innovation, INVO Fertility faces significant financial challenges with Q2 2025 revenue of $1.86 million and a $3.2 million net loss [8], having experienced seven consecutive years of losses.

The PRP therapy’s clinical validation remains experimental [10], creating both market opportunity and regulatory uncertainty. The therapy’s cost-effectiveness relative to advanced reproductive technologies [10] and integration with existing INVOcell technology [10] provide competitive advantages in an emerging market segment with relatively low implementation barriers for competitors.

Market adoption will depend on clinical evidence accumulation, insurance coverage development, and patient awareness efforts [10]. The company’s ongoing operational streamlining and focus on core fertility operations [9] could support successful implementation despite financial constraints.